sar425899 glucagon glp-1 dual agonist sanofi Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy | Diabetologia Focus on Glucagon-like Peptide-1 Target:
Description
Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials
The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).
GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity
or oral administration
Are you a candidate?
This formula is designed to naturally enhance your bodys GLP-1 hormone productiona key factor in
